New stem cell filter could reduce transplant rejection

NCT ID NCT03626285

AVAILABLE Disease control Sponsor: OHSU Knight Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This study offers a special stem cell transplant to people with cancer or other disorders who lack a perfectly matched donor. Doctors use a device to purify stem cells from a partially matched donor, removing immune cells that can cause rejection or attack the patient's body. The goal is to make the transplant safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD34-selected peripheral blood stem cells
What this could lead to: If successful, this approach could make stem cell transplants safer and more available for patients who lack a perfectly matched donor.
What could go wrong: This is an early access protocol, not a controlled trial, so results are uncertain. Risks include graft failure, infection, and graft-versus-host disease despite the CD34 selection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BENIGN NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign neoplasm cancer disease neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BENIGN NEOPLASM BONE MARROW TRANSPLANTATION RECIPIENT HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT MALIGNANT NEOPLASM

New stem cell filter could reduce transplant rejection

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions